



HNY ICB Committee Assurance and Escalation Report

Report to: HNY Integrated Care Board

Report from: Pharmacy Services Regulation Committee (Committees in Common across Yorkshire and the Humber)

Date of meeting: 20 August 2024

Committee Chair: Helen Philips, Assistant Director of Primary Care, HNY ICB

Director Sponsor: Helen Philips, Assistant Director of Primary Care, HNY ICB

Author: Hayley Patterson, Programme Lead – Primary Care, HNY ICB

<p>Key agenda items covered by the meeting. <i>(A bulleted list of the key agenda items discussed at the meeting)</i></p>
<ul style="list-style-type: none"> • Haxby Group Pharmacy Ltd – Unforeseen Benefits Application. • Marra Healthcare Ltd - Unforeseen Benefits Application. • The Pharmacy Group Corporation Ltd - Unforeseen Benefits Application.
<p>ALERT <i>(BY EXCEPTION ONLY - key matters and / or risks to alert or escalate to the ICB Board)</i></p>
<ul style="list-style-type: none"> • No items
<p>ADVISE AND / OR ASSURE <i>(BY EXCEPTION ONLY - Key decisions and any updates to advise the ICB Board on the matters the Committee was able to take assurance on or where additional information was required)</i></p>
<p>Haxby Group Pharmacy Ltd – Unforeseen Benefits Application. The committee did not support this application as the applicant has not demonstrated any unforeseen benefits as required by Regulation 18 of the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013.</p> <p>18(1)(a) – there would not be any improvements or better access by granting this application. 18(1)(b) – there are no improvements or better access included in the current PNA. 18(2)(a)(i-ii) – no determination can be given in relation to whether granting the application would cause significant detriment to either planning for pharmacy services or for pharmacy services already in place. 18(2)(b)(i) - there is reasonable choice in relation to obtaining pharmaceutical services in the area within 1.5miles of the secured premises with good weekday and Saturday access. 18(2)(b)(ii) – there was no information to evidence how people with protected characteristics would access services to meet specific needs. 18(2)(b)(iii) – there was no evidence to support innovative approaches to the delivery of pharmaceutical services</p> <p>Marra Healthcare Ltd - Unforeseen Benefits Application. The committee did not support this application as the applicant has not demonstrated any unforeseen benefits as required by Regulation 18 of the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013.</p>

18(1)(a) – there would not be any improvements or better access by granting this application.
18(1)(b) – there are no improvements or better access included in the current PNA.
18(2)(a)(i-ii) - no determination can be given in relation to whether granting the application would cause significant detriment to either planning for pharmacy services or for pharmacy services already in place.
18(2)(b)(i) - there is reasonable choice in relation to obtaining pharmaceutical services in the area within 1.5miles of YO30 6EF with good weekday and weekend opening.
18(2)(b)(ii) – there was some consideration in relation to how patients could access services but no information to evidence how people with protected characteristics would access services to meet specific needs.
18(2)(b)(iii) – there was no evidence to support innovative approaches to the delivery of pharmaceutical services

The Pharmacy Group Corporation Ltd - Unforeseen Benefits Application.

The committee did not support this application as the applicant has not demonstrated any unforeseen benefits as required by Regulation 18 of the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013.

18(1)(a) – there would not be any improvements or better access by granting this application.
18(1)(b) – there are no improvements or better access included in the current PNA.
18(2)(a)(i-ii) - no determination can be given in relation to whether granting the application would cause significant detriment to either planning for pharmacy services or for pharmacy services already in place.
18(2)(b)(i) - there is reasonable choice in relation to obtaining pharmaceutical services in the area within 1.5miles of the secured premises with good weekday and Saturday opening with some on a Sunday.
18(2)(b)(ii) – there was no information to evidence how people with protected characteristics would access services to meet specific needs.
18(2)(b)(iii) – there was no evidence to support innovative approaches to the delivery of pharmaceutical services

END.